Our founders created the THIOMAB platform to develop site-specific antibody-drug conjugation technology and common light chain libraries in their previous/current industry/academic careers. We bring together more than 40 years in Antibody innovation, Linker technology and Antibody Drug Conjugate (ADC) drug development.

Aarvik Next Generation Approach

Aarvik Strategy to Improve the Therapeutic Index

Aarvik has developed disruptive antibody engineering platforms that create function blocking antibodies, ADCs and other modalities.

Stay tuned as we disclose more details about these revolutionary platforms.